相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nanotized PPARα Overexpression Targeted to Hypertrophied Myocardium Improves Cardiac Function by Attenuating the p53-GSK3β-Mediated Mitochondrial Death Pathway
Santanu Rana et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection
Laura Castiglioni et al.
JOURNAL OF HYPERTENSION (2018)
Peroxisome proliferator-activated receptor-α expression induces alterations in cardiac myofilaments in a pressure-overload model of hypertrophy
Chehade N. Karam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment
Paula S. Azevedo et al.
ARQUIVOS BRASILEIROS DE CARDIOLOGIA (2016)
Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II
Takehiko Takayanagi et al.
HYPERTENSION (2016)
Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis via Inhibiting NF-κB Activation
Xi Chen et al.
MEDIATORS OF INFLAMMATION (2014)
HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
Zhankui Jia et al.
PPAR RESEARCH (2014)
Upregulation of Nox4 Promotes Angiotensin II- Induced Epidermal Growth Factor Receptor Activation and Subsequent Cardiac Hypertrophy by Increasing ADAM17 Expression
Si-Yu Zeng et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4
Jian Zou et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Tumor Necrosis Factor-α Converting Enzyme Inactivation Ameliorates High-Fat Diet-Induced Insulin Resistance and Altered Energy Homeostasis
Hidehiro Kaneko et al.
CIRCULATION JOURNAL (2011)
MMP-2 Mediates Angiotensin II-Induced Hypertension Under the Transcriptional Control of MMP-7 and TACE
Jeffrey Odenbach et al.
HYPERTENSION (2011)
Heart Disease and Stroke Statistics-2009 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Donald Lloyd-Jones et al.
CIRCULATION (2009)
Tumor Necrosis Factor-alpha-Converting Enzyme Is a Key Regulator of Agonist-Induced Cardiac Hypertrophy and Fibrosis
Xiang Wang et al.
HYPERTENSION (2009)
Emerging role of PPAR ligands in the management of diabetic nephropathy
Pitchai Balakumar et al.
PHARMACOLOGICAL RESEARCH (2009)
Cardiac hypertrophy is enhanced in PPARα-/- mice in response to chronic pressure overload
Pascal J. H. Smeets et al.
CARDIOVASCULAR RESEARCH (2008)
Bone marrow-derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload
Jin Endo et al.
CIRCULATION (2007)
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension
Nathan K. LeBrasseur et al.
HYPERTENSION (2007)
Peroxisome proliferator-activated receptor α-independent actions of Fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload
Toni-Ann S. Duhaney et al.
HYPERTENSION (2007)
Cardiac PPARα expression in patients with dilated cardiomyopathy
Michael Schupp et al.
EUROPEAN JOURNAL OF HEART FAILURE (2006)
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators
SH Han et al.
HYPERTENSION (2005)
An optimized protocol for culture of cardiomyocyte from neonatal rat
Jiajia Fu et al.
CYTOTECHNOLOGY (2005)
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
U Sahin et al.
JOURNAL OF CELL BIOLOGY (2004)
Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-α partly via blockade of c-Jun NH2-terminal kinase pathway
Y Irukayama-Tomobe et al.
CIRCULATION (2004)
PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats
QN Diep et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway
L Hao et al.
CIRCULATION RESEARCH (2004)
Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
M Iglarz et al.
HYPERTENSION (2003)
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
M Iglarz et al.
HYPERTENSION (2003)
The ADAMs family of metalloproteases: multidomain proteins with multiple functions
DF Seals et al.
GENES & DEVELOPMENT (2003)
Fenofibrate increases creatininemia by increasing metabolic production of creatinine
C Hottelart et al.
NEPHRON (2002)
Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts
T Ogata et al.
CLINICAL SCIENCE (2002)
The cardiac phenotype induced by PPAR alpha overexpression mimics that caused by diabetes mellitus
BN Finck et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
M Asakura et al.
NATURE MEDICINE (2002)
A novel mouse model of lipotoxic cardiomyopathy
HC Chiu et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
JN Cohn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
分享论文
